Davut Pehlivan
Neurology with Special Qualifications in Child Neurology · Houston, TXNPI 1558707711
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,340 of the $2,207 with a category attached, or 60.7%. Ionis Pharmaceuticals, Inc. accounts for 68.7% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $1,558, more than ten times the $14 reported in 2023.
Across 14 payments — averaging $157.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ionis Pharmaceuticals, Inc.$2K
- Acadia Pharmaceuticals Inc$692
Across 21 payments — averaging $49,614 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ionis Pharmaceuticals, Inc.$1M
What the payments were for
- Consulting fees$30014%
- Speaking & faculty fees$30014%
- Travel & lodging$1,34061%
- Food & beverage$26712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ionis Pharmaceuticals, Inc. | 9 | $1,515 |
| Acadia Pharmaceuticals Inc | 5 | $692 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAYBUE$600
How this compares
$2,207 in reported general payments places this provider in the 60th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DaybueTrofinetide | 37 | $1,897,876 |
| KeppraLevetiracetam | 12 | $22,694 |
| Clobazam | 32 | $4,080 |
| Lamotrigine | 19 | $683 |
| Levetiracetam | 20 | $475 |
| Trazodone Hcl | 15 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncDaybue | $692 | $1,897,87637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
Other neurology with special qualifications in child neurology in Houston
- Huda ZoghbiHouston$5.5M
- Shade MoodyHouston$194K
- Mary Kay KoenigHouston$171K
- Gretchen von AllmenHouston$31K
- Victoria HardwickHouston$10K
- Joshua RotenbergHouston$9K
- Mered ParnesHouston$5K
- Sarah WilsonHouston$5K
- Roy EltermanDallas$5.9M
- Diana CastroDenton$343K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.